In mid-January 2026, Bernstein upgraded Vertex Pharmaceuticals to Outperform and UBS initiated coverage with a Buy rating, ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

CEO David DeStefano highlighted Vertex's strong start to 2025, reporting $177.1 million in revenue, a 12.9% year-over-year increase, supported by 14.4% growth in subscription revenue and 29.6% growth ...

Vertex Pharmaceuticals (VRTX) is back in focus after Wolfe Research upgraded the stock to Outperform, citing increased ...

Vertex Pharmaceuticals Incorporated (VRTX) is a good speculative biotech play to look into. That's because it is doing well in the Cystic Fibrosis [CF] space. It will still continue to do well with ...

Vertex Pharmaceuticals stock declined almost 13% in six months due to poor test results for a new drug. When it comes to the drug and biotech sector, a major pipeline setback can hit the stock hard.

Vertex enjoys a monopoly that could soon grow stronger. The company could have multiple potential blockbuster drugs on the way. Vertex's valuation is attractive factoring in its growth prospects. But ...

BMO Capital Markets analyst Daniel Jester reiterated the Market Perform rating on Vertex, Inc. (NASDAQ:VERX), raising the price target to $28 from $24. Investors rewarded the consistent execution ...

Vertex Pharmaceuticals (VRTX) delivered strong third-quarter results for 2025, surpassing analysts’ expectations with an earnings per share (EPS) of $4.80 against a forecast of $4.57, marking a 5.03% ...

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...